PDL BioPharma: A portfolio of patents
With antibodies produced from mouse and human components, this biotech is advancing drug research.
A major trend in the pharmaceutical business has been toward tailoring treatment to fit an individual patient's biology and disease. As a result, advanced biotechnology has come to play an increasingly critical role in the health care sector.
PDL BioPharma (PDLI) owns a portfolio of patents covering the production of "humanized antibodies," which are a mixture of mouse and human components. Antibodies are the gendarmerie of our immune systems. Each antibody fights a particular sort of pathogenic invader by binding with specific proteins.
Using antibodies to fight specific diseases has become a cornerstone of personalized medicine and the basis of several next-generation drugs for the treatment of cancer, multiple sclerosis and other diseases.
However, the antibodies used in those drugs are derived from mice, which means our immune systems often recognize them as foreign invaders and destroy them.
That biological response can be overcome by PDL's process of humanization, which essentially reorganizes the antibodies' proteins into a more human form, thereby tricking an immune system into believing the mice antibodies belong within the host.
Several major drug companies -- including Roche and Genentech, Wyeth (PFE) and Novartis (NVS) -- have licensed PDL's technology to produce blockbuster drugs such as the cancer treatment Herceptin, the macular degenerative disease treatment Lucentis and the asthma drug Xolair.
The technology is also used to produce Perjeta, a breast cancer treatment that was approved in early June and is widely predicted to become a blockbuster drug with annual sales in excess of $1 billion.
Under licensing agreements, PDL collects a sliding percentage of drug sales based on total revenue generated. PDL's revenues have grown an average of 22.4% over the past five years.
Annual revenue growth is expected to slow to about 13%, as the current slate of drugs incorporating PDL's technology mature. However, it's unlikely that PDL won't strike new licensing deals, because a growing number of new drugs incorporate antibodies.
PDL is trading at its lowest valuation in several years, with a price-to-earnings ratio of 5.6. The company also offers an attractive 15-cent quarterly dividend, which amounts to a yield of about 9%. PDL BioPharma is a buy under $7.
More from TheStockAdvisors
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Tighter regulations and the end of a lengthy bull market in bonds have changed the landscape forever.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.